IAN MORTIMER - 09 Mar 2026 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
09 Mar 2026
Net transactions value
-$16,966,500
Form type
4
Filing time
11 Mar 2026, 19:20:23 UTC
Previous filing
09 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MORTIMER IAN PRESIDENT & CEO, Director 3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA /s/ Nathaniel Adams, Attorney-in-fact 11 Mar 2026 0001619961

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise +75,000 +1250% $8.40* 81,000 09 Mar 2026 Direct
transaction XENE Common Shares Sale $1,281,529 -21,791 -27% $58.81 59,209 09 Mar 2026 Direct F1, F2
transaction XENE Common Shares Sale $1,897,837 -31,694 -54% $59.88 27,515 09 Mar 2026 Direct F1, F3
transaction XENE Common Shares Sale $1,301,442 -21,515 -78% $60.49 6,000 09 Mar 2026 Direct F1, F4
transaction XENE Common Shares Options Exercise +25,000 +417% $3.10* 31,000 09 Mar 2026 Direct
transaction XENE Common Shares Sale $742,500 -12,479 -40% $59.50 18,521 09 Mar 2026 Direct F1, F5
transaction XENE Common Shares Sale $609,054 -10,072 -54% $60.47 8,449 09 Mar 2026 Direct F1, F6
transaction XENE Common Shares Sale $150,026 -2,449 -29% $61.26 6,000 09 Mar 2026 Direct F1, F7
transaction XENE Common Shares Options Exercise +105,000 +1750% $4.75* 111,000 09 Mar 2026 Direct
transaction XENE Common Shares Sale $2,568,802 -43,348 -37% $59.26 72,652 09 Mar 2026 Direct F1, F8
transaction XENE Common Shares Sale $3,704,052 -61,652 -91% $60.08 6,000 09 Mar 2026 Direct F1, F9
transaction XENE Common Shares Options Exercise +65,000 +1083% $9.44* 71,000 09 Mar 2026 Direct
transaction XENE Common Shares Sale $4,033,900 -65,000 -92% $62.06 6,000 09 Mar 2026 Direct F1, F10
transaction XENE Common Shares Options Exercise +20,000 +333% 26,000 09 Mar 2026 Direct F11
transaction XENE Common Shares Sale $677,357 -11,269 -43% $60.11 14,731 10 Mar 2026 Direct F12
holding XENE Common Shares 14,300 09 Mar 2026 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option Options Exercise -75,000 -100% $0.000000* 0 09 Mar 2026 Common Shares 75,000 $8.40 Direct F13
transaction XENE Stock Option Options Exercise -25,000 -100% $0.000000* 0 09 Mar 2026 Common Shares 25,000 $3.10 Direct F13
transaction XENE Stock Option Options Exercise -105,000 -100% $0.000000* 0 09 Mar 2026 Common Shares 105,000 $4.75 Direct F13
transaction XENE Stock Option Options Exercise -65,000 -100% $0.000000* 0 09 Mar 2026 Common Shares 65,000 $9.44 Direct F13
transaction XENE Performance Share Units Award +20,000 $0.000000* 20,000 09 Mar 2026 Common Shares 20,000 Direct F11
transaction XENE Performance Share Units Options Exercise -20,000 -100% $0.000000* 0 09 Mar 2026 Common Shares 20,000 Direct F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024.
F2 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $58.16 to $59.1425, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $59.16 to $60.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $60.16 to $61.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $59.03 to $60.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $60.05 to $61.035, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $61.055 to $61.555, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F8 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $58.745 to $59.735, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F9 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $59.75 to $60.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F10 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.30, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F11 Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination.
F12 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of PSUs granted on March 11, 2024.
F13 The shares subject to this option are fully vested and exercisable.